ARCT - Arcturus Therapeutics Holdings Inc logo

ARCT

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics develops messenger RNA medicines, focusing on therapeutics for rare liver and respiratory diseases, including cystic fibrosis and OTC deficiency. It also creates mRNA vaccines for COVID-19 and seasonal influenza.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 10 years ago โ†’$217today

Score Overview

1 Year
Score
Net Growth18.73%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-51.43%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.5
Net Growth8.82%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth7x
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score
Net Growth8.82%
Net Trend40%
Net Income Consistency
Rev Growth7x
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

Arcturus Therapeutics Holdings Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 9M to $ 67M and net income went from -$ 72M to -$ 65M. Revenue increased in 2 of those 5 years; net income in 2.

Arcturus Therapeutics Holdings Inc currently holds a 5-year HDB Score of 4.5 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 7.60โ€”
1 Year2025-08-12
$ 14.89-48.96%
5 Years2021-08-12
$ 49.94-84.78%
10 Years2016-08-12
$ 35.07-78.33%
All Time2020-04-16
$ 17.00-55.29%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 67M-$ 65M$ 230M
2024$ 138M-$ 80M$ 237M
2023$ 157M-$ 29M$ 292M
2022$ 205M$ 9M$ 391M
2021$ 12M-$ 203M$ 370M
IPO2020$ 9M-$ 72M$ 462M

Explore beyond ARCT

You're looking at Arcturus Therapeutics Holdings Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies